Indication
Cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.
Loading your page…
Loading your page…
Dermatitis, Atopic
Marketing Authorisation Holder: Pfizer Europe MA EEIG
EMA Authorisation: 09/12/2021
INN: abrocitinib
AI Drug & Interaction Analysis
Free account required
Ask Osler about Cibinqo: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.